{"id":"NCT01355484","sponsor":"GTx","briefTitle":"Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC)","officialTitle":"Phase III, Randomized, Double-Blind, Placebo Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Taxane Chemotherapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-07","primaryCompletion":"2013-05","completion":"2014-06","firstPosted":"2011-05-18","resultsPosted":"2016-03-03","lastUpdate":"2016-03-03"},"enrollment":321,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Muscle Wasting","Non Small Cell Lung Cancer"],"interventions":[{"type":"DRUG","name":"GTx-024","otherNames":[]},{"type":"DRUG","name":"placebo","otherNames":[]}],"arms":[{"label":"GTx-024","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to determine if the investigational drug GTx-024 can help subjects with non-small cell lung cancer increase physical function and maintain or gain muscle, also called \"lean body mass\".","primaryOutcome":{"measure":"Physical Function","timeFrame":"Day 84","effectByArm":[{"arm":"GTx-024","deltaMin":29.4,"sd":null},{"arm":"Placebo","deltaMin":24.2,"sd":null}],"pValues":[]},"eligibility":{"minAge":"30 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":13,"exclusionCount":12},"locations":{"siteCount":27,"countries":["United States"]},"refs":{"pmids":["27138015"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":56,"n":160},"commonTop":["Nausea","Alopecia","Anaemia","Vomiting","Disease Progression"]}}